Our focus

We primarily concentrate on gastroenterology and hepatology. But our scope is broad, covering fields as diverse as cardiology, neurology, CNS and more.

With operations in more than thirty countries, PRO.MED.CS medicines are used to treat more than two million patients around the world every day.

Porfolio
1989 year of establishment
PRAGUE CZECH REPUBLIC
our headquarters

Our products

Our portfolio of value-added generic medicines primarily addresses problems of patients suffering from diseases in the gastrointestinal and hepatobiliary tracts, but our product range extends to patient care in cardiology, psychiatry, urology and other conditions.

By maintaining a continuous focus on identifying novel treatments and indications, we are committed to bringing innovative and affordable medicines to patients.

Research & innovation

We have our own research and development capacities and an extensive distribution network. Through our concerted efforts we bring efficient therapies to patients around the world. We provide longstanding support to research teams and independent laboratories in the search for innovative active substances and treatments, and we share the latest findings with scientists and physicians around the world.

Partnership
"/>
PRO.MED.CS WORLDWIDE

Locations

We market our medicinal products in more than thirty countries via our own branch network in Europe and the Eurasian Economic Union and through partners in the rest of the world. Hand-in-hand with our company’s growth, we seek opportunities to expand our portfolio and presence around the world.

Australia Austria Azerbaijan Belarus Bosnia and Herzegovina Bulgaria China Czech Republic Estonia Georgia Germany Kazakhstan Kyrgyzstan Latvia Lithuania Malaysia Moldova Mongolia Netherlands New Zealand Poland Russian Federation Serbia Slovakia Slovenia Sweden Tunisia Ukraine United Arab Emirates United Kingdom Uzbekistan

A fully integrated pharmaceutical company

We have our own research and development capacities and an extensive distribution network. Through our concerted efforts, we bring therapies to patients around the world.

We handle the entire marketing authorisation process for new medicinal products as well as extensions of marketing authorisations for existing medicinal products in new territories.

We specialise in developing dosage forms, prepare in-house formulations and pre-formulations, conduct studies, and procure marketing authorisations worldwide.

Our excellent logistics guarantees a high standard of warehousing and distribution operations while upholding the strictest GMP and GDP standards to satisfy all our customers and business partners.

We make sure that our medicinal products are manufactured as efficiently as possible, but also with the highest level of quality.

We ensure that all links in our distribution chain run smoothly so that patients around the world can receive their medicines at the right place and at the right time.

Our annual production exceeds one billion tablets, film-coated tablets, capsules, vials and suppositories. All our operations and practices comply with GMP, GLP and GDP standards.

Our history

From small start-up to international business

The company was established on 1 February 1989 and launched its first medicine the following year. Obtaining the international certificate of Good Manufacturing Practice led to its dynamic growth in foreign markets.

Although the company has grown and expanded operations worldwide, we remain as committed as ever to high-quality manufacturing and processes that put our customers first. Like a good family, we care about the future, prosperity, satisfaction, and health of our employees.

1990
First marketing authorisation (Ranisan)
1992
Ursosan first approved for use
1994
GMP (Good Manufacturing Practice) certification
1996
Entrance on the Russian, Polish and Kazakh markets
2000
GDP (Good Distribution Practice) certification
2010
Twenty-three brands of medicine in our portfolio
2012
Extension of export to the German and Australian markets
2017
GMP certification for Russia
2019
Entrance on the UK market
2020
Fifty brands of medicine marketed in 30 countries around the world

We’re socially responsible

We enjoy supporting charitable activities, organisations and groups that selflessly help the community.

We have supported:

PRO.MED.CS is helping residents of Ukraine

Tens of thousands of packages of antibiotics, analgesics for emergency pain relief, anti-infectives, adrenaline, and medicines to treat cystic fibrosis are among the nearly eight hundred thousand packages of medicinal products that pharmaceutical companies have donated to Ukraine since early March under a project coordinated by the Czech Ministry of Health.